Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes

被引:15
|
作者
Shek, Dmitrii [1 ,2 ,3 ]
Akhuba, Liia [3 ]
Carlino, Matteo S. [2 ,4 ,5 ,6 ]
Nagrial, Adnan [2 ,4 ,5 ]
Moujaber, Tania [2 ,4 ]
Read, Scott A. [1 ,2 ,7 ]
Gao, Bo [2 ,4 ]
Ahlenstiel, Golo [1 ,2 ,5 ,7 ]
机构
[1] Univ Western Sydney, Blacktown Clin Sch, Sydney, NSW 2148, Australia
[2] Blacktown Hosp, Sydney, NSW 2148, Australia
[3] RUDN Univ, Accreditat Ctr, Moscow 117198, Russia
[4] Westmead Hosp, Crown Princess Mary Canc Ctr, Sydney, NSW 2145, Australia
[5] Univ Sydney, Westmead Clin Sch, Sydney, NSW 2145, Australia
[6] Melanoma Inst, Sydney, NSW 2065, Australia
[7] Storr Liver Ctr, Westmead Inst Med Res, Sydney, NSW 2145, Australia
关键词
colorectal cancer; pembrolizumab; atezolizumab; nivolumab; ipilimumab; targeted therapy; immune-checkpoint inhibitors; NIVOLUMAB; SURVIVAL; VEGF;
D O I
10.3390/cancers13174345
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary In 2018, colorectal cancer (CRC) was declared the fourth most deadly cancer worldwide. Unfortunately, a quarter of all patients are diagnosed at late stages, when curative surgery is not possible, rendering systemic therapy and/or best supportive care as the only options. To our knowledge, this is the first systematic review assessing response and survival rates in patients with mCRC treated with immune-checkpoint inhibitors (ICIs). Our study established that ICIs show potentially superior response rates in mCRC patients, though only in those with high microsatellite instability (MSI). Nivolumab + regorafenib was reported to provide encouraging response in low-MSI (MSI-L) patients; however, additional studies using cohort randomization are required. Further studies are required, particularly regarding the mechanism of resistance to ICIs in MSI-L patients. Background. Colorectal cancer (CRC) is the fourth most deadly cancer worldwide. Unfortunately, a quarter of the patients are diagnosed at late stages, when surgical options are limited. Targeted therapies, particularly immune-checkpoint inhibitors (ICIs), are the latest addition and have been studied herein regarding their efficacy outcomes. Methods. Clinical studies were identified through the PubMed, Scopus and Cochrane databases. Any trial that evaluated ICIs in patients with metastatic CRC (mCRC) and reported the objective response rate was deemed eligible. Data analysis was performed by employing the random-effects model in STATA v.17. Results. A total of 461 articles were identified; 13 clinical trials were included, encompassing a total cohort of 1209 patients. Our study determined that a single PD-1/PD-L1 checkpoint blockade provides durable clinical response in mCRC patients with high microsatellite instability (MSI-H). The combinatorial therapy of CTLA-4 + PD-1 inhibitors also showed high response rates in pre-treated MSI-H patients. The single-arm REGONIVO trial reported durable clinical response in patients with microsatellite stable (MSS) status. Conclusions. Our study surmises that PD-1/PD-L1 inhibitors as well as combination therapy with CTLA-4 and PD-1 inhibitors show encouraging response rates in mCRC patients, albeit exclusively in patients with cancer that are of MSI-H status. A single study suggests that nivolumab + regorafenib can reach a durable response rate in MSS patients; however, further studies in larger randomized settings are required.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review
    Guven, Deniz Can
    Kavgaci, Gozde
    Erul, Enes
    Syed, Masood Pasha
    Magge, Tara
    Saeed, Anwaar
    Yalcin, Suayib
    Sahin, Ibrahim Halil
    ONCOLOGIST, 2024, : e580 - e600
  • [32] Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis
    Yu, Hang
    Liu, Qingquan
    Wu, Keting
    Tang, Shuang
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [33] Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis
    Xia, Handai
    Zhang, Wengang
    Zhang, Yuqing
    Shang, Xiaoling
    Liu, Yanguo
    Wang, Xiuwen
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [34] Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
    Palmer, Adam C.
    Izar, Benjamin
    Hwangbo, Haeun
    Sorger, Peter K.
    CLINICAL CANCER RESEARCH, 2022, 28 (02) : 368 - 377
  • [35] New Zealand national retrospective cohort study of survival outcomes of patients with metastatic melanoma receiving immune-checkpoint inhibitors
    Ab Rahman, Ahmad Sufian
    Strother, Robert Matthew
    Paddison, Johanna
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 (01) : 179 - 186
  • [36] Role of immune-checkpoint inhibitors in lung cancer
    Jain, Prantesh
    Jain, Chhavi
    Velcheti, Vamsidhar
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2018, 12
  • [37] A decade of immune-checkpoint inhibitors in cancer therapy
    Robert, Caroline
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [38] Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review
    Abdel-Rahman, Omar
    Eltobgy, Mostafa
    Oweira, Hani
    Giryes, Anwar
    Tekbas, Aysun
    Decker, Michael
    IMMUNOTHERAPY, 2017, 9 (14) : 1175 - 1183
  • [39] Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
    Nasca, Vincenzo
    Barretta, Francesco
    Corti, Francesca
    Lonardi, Sara
    Niger, Monica
    Elez, Maria Elena
    Fakih, Marwan
    Jayachandran, Priya
    Shah, Aakash Tushar
    Salati, Massimiliano
    Fenocchio, Elisabetta
    Salvatore, Lisa
    Cremolini, Chiara
    Ros, Javier
    Ambrosini, Margherita
    Mazzoli, Giacomo
    Intini, Rossana
    Overman, Michael J.
    Miceli, Rosalba
    Pietrantonio, Filippo
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
  • [40] Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review
    Mallio, Carlo Augusto
    Bernetti, Caterina
    Cea, Laura
    Buoso, Andrea
    Stiffi, Massimo
    Vertulli, Daniele
    Greco, Federico
    Zobel, Bruno Beomonte
    CURRENT ONCOLOGY, 2023, 30 (05) : 4700 - 4723